Sustained clinical remission and rate of relapse after tocilizumab withdrawal in patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 40, Issue 7, 2013, Pages 1069-1073

  Aguilar Lozano, Luis ^a   Castillo Ortiz, Jose Dionisio ^a   Vargas Serafin, Cesar ^a   Morales Torres, Jorge ^b   Sanchez Ortiz, Adriana ^c   Sandoval Castro, Carlos ^c   Padilla Ibarra, Jorge ^c   Hernandez Cuevas, Claudia ^c   Ramos Remus, Cesar ^a,c  

^a Unidad de Investigacion en Enfermedades Cronico Degenerativas   (Mexico)

^b Hospital Aranda de la Parra   (Mexico)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Biological Agent; Relapse; Remission; Rheumatoid Arthritis; Tocilizumab; Withdrawal

Indexed keywords

ANTIINFLAMMATORY AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; METHOTREXATE; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DAS28; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; JOINT SWELLING; MALE; MEXICO; MULTICENTER STUDY (TOPIC); OPEN STUDY; PATIENT MONITORING; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REMISSION; RETREATMENT; RHEUMATOID ARTHRITIS; TREATMENT DURATION;

BIOLOGICAL AGENT; RELAPSE; REMISSION; RHEUMATOID ARTHRITIS; TOCILIZUMAB; WITHDRAWAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879941145     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121427     Document Type: Article

References (27)

1. Badley EM. Rheumatic diseases: The unnoticed elephant in the room. J Rheumatol 2008;35:6-7.
2. Loza E, Abasolo L, Jover JA, Carmona L; EPISER Study Group. Burden of disease across chronic diseases: A health survey that measured prevalence, function, and quality of life. J Rheumatol 2008;35:159-65.
3. Ramos-Remus C, Sierra-Jimenez G, Skeith K, Aceves-Avila FJ, Russell AS, Offer R, et al. Latitude gradient influences the age of onset in rheumatoid arthritis patients. Clin Rheumatol 2007;26:1725-8.
4. Chatzidionysiou K, van Vollenhoven RF. When to initiate and discontinue biologic treatments for rheumatoid arthritis? J Intern Med 2011;269:614-25.
5. Saleem B, Keen H, Goeb V, Parmar R, Nizam S, Hensor EM, et al. Patients with RA in remission on TNF blockers: When and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 2010;69:1636-42.
6. van den Broek M, Lems WF, Allaart CF. Do we need guidelines to stop as well as to start biological therapies for rheumatoid arthritis? Clin Exp Rheumatol 2012;30 Suppl 73:S21-6.
7. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625-39.
8. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:27-35.
9. van den Broek M, Klarenbeek NB, Dirven L, van Schaardenburg D, Hulsmans HM, Kerstens PJ, et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and Disease Activity Score-steered therapy: Subanalysis of the BeSt study. Ann Rheum Dis 2011;70:1389-94.
10. Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis, RRR (remission induction by remicade in RA) Study. Ann Rheum Dis 2010;69:1286-91.
11. van der Maas A, Kievit W, van den Bemt BJ, van den Hoogen FH, van Riel PL, den Broeder AA. Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: An observational cohort study. Ann Rheum Dis 2012;71:1849-54.
12. Kavanaugh A, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P, et al. Withdrawal of adalimumab in early rheumatoid arthritis patients who attained stable low disease activity with adalimumab plus methotrexate: Results of a phase 4, double-blind, placebo-controlled study [abstract]. Arthritis Rheum 2011;63 Suppl:665-6.
13. Harigai M, Takeuchi T, Tanaka Y, Matsubara T, Yamanaka H, Miyasaka N. Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Mod Rheumatol 2012;22:814-22.
14. Tanaka Y, Hirata S, Fukuyo S, Nawata M, Kubo S, Yamaoka K. Discontinuation of adalimumab without functional and structural progress after attaining remission in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2011;63 Suppl:962.
15. Nishimoto N. Drug free remission after cessation of actemra monotherapy (DREAM study) [abstract]. Ann Rheum Dis Suppl 2010;69 Suppl 3:98.
16. Buch MH, Marzo-Ortega H, Bingham SJ, Emery P. Long-term treatment of rheumatoid arthritis with tumor necrosis factor alpha blockade: Outcome of ceasing and restarting biologicals. Rheumatology 2004;43:243-4.
17. Brocq O, Millasseau E, Albert C, Grisot C, Flory P, Roux CH, et al. Effect of discontinuing TNF-alpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 2009;76:350-5.
18. Kaine J, Gladstein G, Strusberg I, Robles M, Louw I, Gujrathi S, et al. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: Impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study). Ann Rheum Dis 2012;71:38-44.
19. Detert J, Bastian H, Listing J, Weiss A, Wassenberg S, Liebhaber A, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 2012 Jul 10. [E-pub ahead of print]
20. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
21. Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: The ROSE study. Ann Rheum Dis 2012;71:198-205.
22. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 2010;69:88-96.
23. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet 2008;371:989-97.
24. Hoffmann-La Roche. Long-term extension study of safety during treatment with tocilizumab in rheumatoid arthritis patients completing treatment in WA17822. [Internet. Accessed April 2, 2013.] Available from: Http://clinicaltrials.gov/show/NCT00721123
25. Hoffmann-La Roche; Long-term extension study of safety during treatment with tocilizumab in rheumatoid arthritis patients completing treatment in tocilizumab core studies WA18062, WA18063 and WA17824. [Internet. Accessed April 2, 2013.] Available from: Http://clinicaltrials.gov/show/NCT00720798
26. Goycochea-Robles MV, Sanin LH, Moreno-Montoya J, Alvarez-Nemegyei J, Burgos-Vargas R, Garza-Elizondo M, et al; Grupo de Estudio Epidemiolóico de Enfermedades Mculo Articulares (GEEMA). Validity of the COPCORD core questionnaire as a classification tool for rheumatic diseases. J Rheumatol Suppl. 2011 Jan;86:31-5.
27. Sagawa A. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: Retreatment of patients with rheumatoid arthritis with a novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: The RONIN study. Mod Rheumatol 2011;21:352-8.